Due to the aging of the populations it is expected an increasingly incidence of cancer in the coming years.And due to the improvement of treatments it is also expected an increasing number of cancer survivors.In addition, cytotoxic agents and targeted therapies used to treat cancer could affect the cardiovascular system.The most known is doxorubicin.Genomic analysis have provided evidence that mitochondria is the primary target of doxorubicin-induced oxidative damage that leads to cardiomyopathy and the primary site of cardioprotective action by dexrazoxane.